Glycogen synthase kinase 3 as an anticancer drug target: Novel experimental findings and trends in the design of inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 4, 2013, Pages 665-679

  Osolodkin, Dmitry I ^a   Palyulin, Vladimir A ^a   Zefirov, Nikolay S ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Cancer treatment; Glycogen synthase kinase 3; Kinase inhibitors; Molecular design; Wnt pathway

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALSTERPAULLONE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; BENZOFURAN 3 YL (INDOL 3 YL)MALEIMIDE; BENZOFURAN DERIVATIVE; CHIR 99021; DOCETAXEL; DW 12; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; L 803; LITHIUM CHLORIDE; MANZAMINE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN C MYB; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; SORAFENIB; TAUTOMYCIN; TDZD 8; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENE EXPRESSION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; QUANTUM MECHANICS; REVIEW; SIGNAL TRANSDUCTION; TREND STUDY;

EID: 84876737705     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128130407     Document Type: Review

References (175)

1. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107: 519-27.
2. Avila J, Wandosell F, Hernández F. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother 2010; 10: 703-10.
3. Wagman AS, Johnson KW, Bussiere DE. Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes. Curr Pharm Des 2004; 10: 1105-37.
4. Henriksen EJ, Dokken BB. Role of Glycogen Synthase Kinase-3 in Insulin Resistance and Type 2 Diabetes. Curr Drug Targets 2006; 7: 1435-41.
5. Dugo L, Collin M, Thiemermann C. Glycogen Synthase Kinase 3β as a Target for the Therapy of Shock and Inflammation. Shock 2007; 27: 113-23.
6. Klamer G, Song E, Ko KH, OBrien TA, Dolnikov A. Using Small Molecule GSK3β Inhibitors to Treat Inflammation. Curr Med Chem 2010; 17: 2873-81.
7. Miura T, Nishihara M, Miki T. Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway: Role of GSK-3β in Myocardial Protection Against Ischemia/Reperfusion Injury. J Pharmacol Sci 2009; 109: 162-7.
8. Giese KP. GSK-3: A key player in neurodegeneration and memory. IUBMB Life 2009; 61: 516-521.
9. Fu Y, Zheng S, An N, et al. β-catenin as a potential key target for tumor suppression. Int J Cancer 2011; 129: 1541-51.
10. Li Y, Yokohama-Tamaki T, Tanaka TS. Short-Term Serum-Free Culture Reveals that Inhibition of Gsk3β Induces the Tumor-Like Growth of Mouse Embryonic Stem Cells. PLoS ONE, 2011; 6: e21355.
11. Ougolkov AV, Billadeau DD. Targeting GSK-3: a promising approach for cancer therapy? Future Oncol 2006; 2: 91-100.
12. Martinez A. Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs. Med Res Rev 2008; 28: 773-96.
13. Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel 2008; 11: 533-43.
14. Eldar-Finkelman H, Martinez A. GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 2011; 4: 32.
15. Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN. GSK3: role in therapeutic landscape and development of modulators. Br J Pharm 2010; 160: 1-19.
16. Luo J. Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273: 194-200.
17. Miyashita K, Nakada M, Shakoori A, et al. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. Anticancer Agents Med Chem 2009; 9: 1114-22.
18. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Molecular Cancer 2010; 9: 144.
19. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/Factor A. EMBO J 1990; 9: 2431-8.
20. Wood-Kaczmar A, Kraus M, Ishiguro K, Philpott KL, Gordon-Weeks PR. An alternatively spliced form of glycogen synthase kinase-3α is targeted to growing neurites and growth cones. Mol Cell Neurosci 2009; 42: 184-94.
21. Liang MH, Chuang DM. Differential Roles of Glycogen Synthase Kinase-3 Isoforms in the Regulation of Transcriptional Activation. J Biol Chem 2006; 281: 30479-84.
22. Lau KF, Miller CC, Anderton BH, Shaw PC. Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res 1999; 54: 85-91.
23. Zhou J, Lal H, Chen X, et al. GSK-3alpha directly regulates betaadrenergic signaling and the response of the heart to hemodynamic stress in mice. J Clin Invest 2010; 120: 2280-91.
24. Kerkela R, Kockeritz L, Macaulay K, et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 2008; 118: 3609-18.
25. Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
26. Peineau S, Bradley C, Taghibiglou C, et al. The role of GSK-3 in synaptic plasticity. Br J Pharm 2008; 153: S428-37.
27. Hernández F, Langa E, Cuadros R, Avila J, Villanueva N. Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem 2010; 344: 211-5.
28. Dajani R, Fraser E, Roe SM, et al. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001; 105: 721-32
29. Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004; 377: 249-55.
30. Thornton TM, Pedraza-Alva G, Deng B, et al. Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3α Inactivation. Science 2008; 320: 667-70.
31. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Research 2000; 28: 235-42.
32. Johnson LN, Lowe ED, Noble MEM, Owen DJ. The structural basis for substrate recognition and control by protein kinases. FEBS Letters 1998; 430: 1-11.
33. Aoki M, Yokota T, Sugiura I, et al. Structural insight into nucleotide recognition in tau protein kinase I/glycogen synthase kinase 3α. Acta Cryst D 2004; 60: 439-46.
34. Bertrand JA, Thieffine S, Vulpetti A, et al. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol 2003; 333: 393-407.
35. Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, Roach PJ. Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase3. J Biol Chem 1987; 262: 14042-48.
36. Bax B, Carter PS, Lewis C, et al. The Structure of Phosphorylated GSK-3α Complexed with a Peptide, FRATtide, that Inhibits α-Catenin Phosphorylation. Structure 2001; 9: 1143-52.
37. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359: 1-16.
38. Palomo V, Soteras I, Perez DI, et al. Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. J Med Chem 2011; 54: 8461-70.
39. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-8.
40. Ryves WJ, Harwood AJ. Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium. Biochem Biophys Res Comm 2001; 280: 720-5.
41. Ryves WJ, Dajani R, Pearl L, Harwood AJ. Glycogen Synthase Kinase-3 Inhibition by Lithium and Beryllium Suggests the Presence of Two Magnesium Binding Sites. Biochem Biophys Res Commun 2002; 290: 967-72.
42. Sun H, Jiang YJ, Yu QS, Luo CC, Zou JW. The effect of Li+ on GSK-3 inhibition: Molecular dynamics simulation. J Mol Model 2011; 17: 377-81.
43. Lu SY, Jiang YJ, Zou JW, Wu TX. Dissection of the difference between the group I metal ions in inhibiting GSK3α: a computational study. Phys Chem Chem Phys 2011; 13: 7014-23.
44. Xingi E, Smirlis D, Myrianthopoulos V, et al. 6-Br-5methylindirubin-3βoxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: Exploitation of GSK-3 for treating leishmaniasis. Int J Parasitol 2009; 39: 1289-303.
45. Osolodkin DI, Zakharevich NV, Palyulin VA, Danilenko VN, Zefirov NS. Bioinformatic analysis of glycogen synthase kinase 3: human versus parasite kinases. Parasitology 2011; 138: 725-35.
46. Kim DJ, Reddy K, Kim MO, et al. (3-Chloroacetyl)-indole, a Novel Allosteric AKT Inhibitor, Suppresses Colon Cancer Growth In Vitro and In Vivo. Cancer Prev Res 2011; 4: 1842-51.
47. Smartt HJM, Greenhough A, Ordóñez-Morán P, et al. α-Catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Gut 2012; 61: 1306-14.
48. Kayser KJ, Glenn MP, Sebti SM, Cheng JQ, Hamilton AD. Modifications of the GSK3α substrate sequence to produce substratemimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorg Med Chem Lett 2007; 17: 2068-73.
49. Ranatunga S, Del Valle JR. Synthesis of GSK3α mimetic inhibitors of Akt featuring a novel extended dipeptide surrogate. Bioorg Med Chem Lett 2011; 21: 7166-9.
50. Kayser-Bricker KJ, Glenn MP, Lee SH, Sebti SM, Cheng JQ, Hamilton AD. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents. Bioorg Med Chem 2009; 17: 1764-71.
51. Morrow JK, Du-Cuny L, Chen L, et al. Recent Development of Anticancer Therapeutics Targeting Akt. Recent Patents on Anti-Cancer Drug Discovery 2011; 6: 146-59.
52. Collins I. Targeted small-molecule inhibitors of protein kinase B as anticancer agents. Anticancer Agents Med Chem 2009; 9: 32-50.
53. Saba NS, Levy LS. Protein Kinase C-Beta Inhibition Induces Apoptosis and Inhibits Cell Cycle Progression in Acquired Immunodeficiency Syndrome-Related Non-Hodgkin Lymphoma Cells. J Investig Med 2012; 60: 29-38.
54. McDonnell SRP, Hwang SR, Basrur V, et al. NPM-ALK signals through glycogen synthase kinase 3α to promote oncogenesis. Oncogene, 2012; 31: 3733-40.
55. Liu J-J, Dai XJ, Xu Y, et al. Inhibition of Lymphoma Cell Proliferation by Peroxisomal Proliferator-Activated Receptor-ć Ligands via Wnt Signaling Pathway. Cell Biochem Biophys 2012; 62: 19-27.
56. Zhang W, Yan S, Liu M, et al. α-Catenin/TCF pathway plays a vital role in selenium induced-growth inhibition and apoptosis in esophageal squamous cell carcinoma (ESCC) cells. Cancer Lett 2010; 296: 113-22.
57. Zhu W, Yan G. The Molecular Mechanism for Differentiation Therapy of Malignant Glioma. In: Abujamra AL, Ed. Brain Tumors-Current and Emerging Therapeutic Strategies. Rijeka: InTech 2011; pp. 67-88.
58. Mills CN, Nowsheen S, Bonner JA, Yang ES. Emerging Roles of Glycogen Synthase Kinase 3 in the Treatment of Brain Tumors. Front Mol Neurosci 2011; 4: 47.
59. Mora-Santos M, Limón-Mortés MC, Giráldez S, et al. Glycogen Synthase Kinase-3α (GSK3α) Negatively Regulates PTTG1/Human Securin Protein Stability, and GSK3α Inactivation Correlates with Securin Accumulation in Breast Tumors. J Biol Chem 2011; 286: 30047-56.
60. Zhai Y, Iura A, Yeasmin S, et al. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid carcinoma. Oncogene 2011; 30: 4152-62.
61. Fang J, Lei W, Huang X, et al. Expression of mismatch repair gene PMS2 in nasopharyngeal carcinoma and regulation by glycogen synthase kinase-3α in vivo and in vitro. Auris Nasus Larynx 2012; 39: 71-6.
62. Liu Q, Mier J, Panka D. Differential Modulatory Effects of GSK-3 beta and HDM2 on Sorafenib-Induced AIF Nuclear Translocation (Programmed Necrosis) in Melanoma. Molecular Cancer 2011; 10: 115.
63. Smalley KSM, Contractor R, Haass NK, et al. An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells. Cancer Res 2007; 67: 209-17.
64. Rinnab L, Schütz SV, Diesch J, et al. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? Neoplasia 2008; 10: 624-34.
65. Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M. Inhibition of Glycogen Synthase Kinase-3α Counteracts Ligand-Independent Activity of the Androgen Receptor in Castration Resistant Prostate Cancer. PLoS ONE 2011; 6: e25341.
66. Zhu Q, Yang J, Han S, et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 2011; 71: 835-45.
67. Garcea G, Manson MM, Neal CP, et al. Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer? Curr Cancer Drug Targets 2007; 7: 209-15.
68. Hamann M, Alonso D, Martín-Aparicio E, et al. Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure-Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer's Disease. J Nat Prod 2007; 70: 1397-405.
69. Guzmán EA, Johnson JD, Linley PA, Gunasekera SE, Wright AE. A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis. Invest New Drugs 2011; 29: 777-85.
70. Marchand B, Tremblay I, Cagnol S, Boucher MJ. Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. Carcinogenesis 2012; 33:529-37.
71. Shimasaki T, Ishigaki Y, Nakamura Y, et al. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. J Gastroenterol 2012; 47:321-33.
72. Mamaghani S, Patel S, Hedley D. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 2009; 9: 132.
73. Kobayashi T, Shimura T, Yajima T, et al. Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin. Int J Cancer 2011; 129: 2775-86.
74. Gaisina IN, Gallier F, Ougolkov AV, et al. From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3β Inhibitors That Suppress Proliferation and Survival of Pancreatic Cancer Cells. J Med Chem 2009; 52: 1853-63.
75. Yohn N, Bingaman C, DuMont A, Yoo L. Phosphatidylinositol 3'-kinase, mTOR, and Glycogen synthase kinase-3beta mediated regulation of p21 in human urothelial carcinoma cells. BMC Urology 2011; 11: 19.
76. Ninomiya S, Shimizu M, Imai K, et al. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells. Cancer Prev Res 2011; 4: 2092-100.
77. Shimizu M, Sakai H, Shirakami Y, et al. Preventive Effects of (β)-Epigallocatechin Gallate on Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-db/db Mice. Cancer Prev Res 2011; 4: 396-403.
78. Liu Z, Brooks RS, Ciappio ED, et al. Diet-induced obesity elevates colonic TNF-β in mice and is accompanied by an activation of Wnt signaling: a mechanism for obesity-associated colorectal cancer. J Nutr Biochem 2012; 23: 1207-13.
79. Deevi R, Fatehullah A, Jagan I, Nagaraju M, Bingham V, Campbell FC. PTEN regulates colorectal epithelial apoptosis through Cdc42 signalling. Br J Cancer 2011; 105: 1313-21.
80. Bilim V, Ougolkov A, Yuuki K, et al. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 2009; 101: 2005-14.
81. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007; 110: 735-42.
82. Tsukigi M, Bilim V, Yuuki K, et al. Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3β. Cancer Lett 2012; 315: 189-97.
83. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TCP, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205-9.
84. Song EY, Palladinetti P, Klamer G, et al. Glycogen synthase kinase-3β inhibitors suppress leukemia cell growth. Experimental Hematology 2010; 38: 908-21.
85. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclindependent kinases. Nat Cell Biol 1999; 1: 60-7.
86. Mirlashari MR, Randen I, Kjeldsen-Kragh J. Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway. Leukemia Research 2012; 36: 499-508.
87. Rådinger M, Smrć D, Metcalfe DD, Gilfillan AM. Glycogen Synthase Kinase-3β Is a Prosurvival Signal for the Maintenance of Human Mast Cell Homeostasis. J Immunol 2011; 187: 5587-95.
88. Zhou F, Zhang L, van Laar T, van Dam H, Dijke PT. GSK3β inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Mol Biol Cell 2011; 22: 3533-40.
89. Adler JT, Cook M, Luo Y, et al. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β. Mol Cancer Ther 2009; 8: 914-20.
90. Bourogaa E, Bertrand J, Despeaux M, et al. Hammada scoparia flavonoids and rutin kill adherent and chemoresistant leukemic cells. Leukemia Research 2011; 35: 1093-101.
91. Davis PD, Hill CH, Lawton G, et al. Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides. J Med Chem 1992; 35: 177-84.
92. Davis PD, Elliott LH, Harris W, et al. Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J Med Chem 1992; 35: 994-1001.
93. Hers I, Tavaré JM, Denton RM. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Letters 1999; 460: 433-6.
94. Leclerc S, Garnier M, Hoessel R, et al. Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease. J Biol Chem 2001; 276: 251-60.
95. Zaharevitz DW, Gussio R, Leost M, et al. Discovery and Initial Characterization of the Paullones, a Novel Class of Small-Molecule Inhibitors of Cyclin-dependent Kinases. Cancer Res 1999; 59: 2566-9.
96. Kunick C, Schultz C, Lemcke T, et al. 2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorg Med Chem Lett 2000; 10: 567-9.
97. Xie X, Lemcke T, Gussio R, et al. Epoxide-containing side chains enhance antiproliferative activity of paullones. Eur J Med Chem 2005; 40: 655-61.
98. Schmöle AC, Brennführer A, Karapetyan G, et al. Novel indolylmaleimide acts as GSK-3β inhibitor in human neural progenitor cells. Bioorg Med Chem 2010; 18: 6785-95.
99. Chen W, Gaisina IN, Gunosewoyo H, Malekiani SA, Hanania T, Kozikowski AP. Structure-Guided Design of a Highly Selective Glycogen Synthase Kinase-3β Inhibitor: a Superior Neuroprotective Pyrazolone Showing Antimania Effects. ChemMedChem 2011; 6: 1587-92.
100. Komander D, Kular GS, Schüttelkopf AW, et al. Interactions of LY333531 and Other Bisindolyl Maleimide Inhibitors with PDK1. Structure 2004; 12: 215-26.
101. Zhang HC, Boñaga LVR, Ye H, Derian CK, Damiano BP, Maryanoff BE. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. Bioorg Med Chem Lett 2007; 17: 2863-8.
102. Gong L, Hirschfeld D, Tan YC, et al. Discovery of potent and bioavailable GSK-3β inhibitors. Bioorg Med Chem Lett 2010; 20: 1693-6.
103. Dessalew N, Bharatam PV. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: An insight into the criteria for selectivity. Eur J Med Chem 2007; 42: 1014-27.
104. Kozikowski AP, Gaisina IN, Yuan H, et al. Structure-Based Design Leads to the Identification of Lithium Mimetics That Block Manialike Effects in Rodents. Possible New GSK-3β Therapies for Bipolar Disorders. J Am Chem Soc 2007; 129: 8328-32.
105. Tsareva DA, Osolodkin DI, Shulga DA, et al. General Purpose Electronegativity Relaxation Charge Models Applied to CoMFA and CoMSIA Study of GSK-3 Inhibitors. Mol Inf 2011; 30: 169-80.
106. Kim KH, Gaisina I, Gallier F, et al. Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3β inhibitors. J Mol Model 2009; 15: 1463-79.
107. Baskin II, Halberstam NM, Mukhina TV, Palyulin VA, Zefirov NS. The Learned Symmetry Concept in Revealing Quantitative Structure-Activity Relationships With Artificial Neural Networks. SAR QSAR Environ Res 2001; 12: 401-16.
108. Feng L, Geisselbrecht Y, Blanck S, et al. Structurally Sophisticated Octahedral Metal Complexes as Highly Selective Protein Kinase Inhibitors. J Am Chem Soc 2011; 133: 5976-86.
109. Meggers E, Atilla-Gokcumen GE, Grundler K, Frias C, Prokop A. Inert ruthenium half-sandwich complexes with anticancer activity. Dalton Trans 2009; 10882-8.
110. Meijer L, Skaltsounis ALL, Magiatis P, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003; 10: 1255-66.
111. Polychronopoulos P, Magiatis P, Skaltsounis AL, et al. Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases. J Med Chem 2004; 47: 935-46.
112. Vougogiannopoulou K, Ferandin Y, Bettayeb K, et al. Soluble 3β,6-Substituted Indirubins with Enhanced Selectivity toward Glycogen Synthase Kinase-3 Alter Circadian Period. J Med Chem 2008; 51: 6421-31.
113. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007; 6: 464-79.
114. Kritsanida M, Magiatis P, Skaltsounis AL, Peng Y, Li P, Wennogle LP. Synthesis and Antiproliferative Activity of 7-Azaindirubin-3β-oxime, a 7-Aza Isostere of the Natural Indirubin Pharmacophore. J Nat Prod 2009; 72: 2199-202.
115. Choi MJ, Oh DW, Jang JW, et al. Synthesis and Biological Evaluation of Novel GSK-3β Inhibitors as Anticancer Agents. Bull Korean Chem Soc 2011; 32: 2015-20.
116. Witherington J, Bordas V, Garland SL, et al. 5-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 2003; 13: 1577-80.
117. Akritopoulou-Zanze I, Wakefield BD, Gasiecki A, et al. Scaffold oriented synthesis. Part 3: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing [2+3]cycloadditions. Bioorg Med Chem Lett 2011; 21: 1476-79.
118. Cociorva OM, Li B, Nomanbhoy T, et al. Synthesis and structure-activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β. Bioorg Med Chem Lett 2011; 21: 5948-51.
119. Li B, Cociorva OM, Nomanbhoy T, et al. 6-Position optimization of tricyclic 4-quinolone-based inhibitors of glycogen synthase kinase-3β: Discovery of nitrile derivatives with picomolar potency. Bioorg Med Chem Lett 2012; 22: 1005-8.
120. Kim HJ, Choo H, Cho YS, No KT, Pae AN. Novel GSK-3β inhibitors from sequential virtual screening. Bioorg Med Chem 2008; 16: 636-43.
121. Vadivelan S, Sinha BN, Tajne S, Jagarlapudi SARP. Fragment and knowledge-based design of selective GSK-3β inhibitors using virtual screening models. Eur J Med Chem 2009; 44: 2361-71.
122. Gentile G, Bernasconi G, Pozzan A, et al. Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors. Bioorg Med Chem Lett 2011; 21: 4823-7.
123. Pierce AC, Sandretto KL, Bemis GW. Kinase inhibitors and the case for CH. O hydrogen bonds in protein-ligand binding. Proteins. 2002; 49: 567-76.
124. Pierce AC, ter Haar E, Binch HM, Kay DP, Patel SR, Li P. CHβO and CHβN Hydrogen Bonds in Ligand Design:β A Novel Quinazolin-4-ylthiazol-2-ylamine Protein Kinase Inhibitor. J Med Chem 2005; 48: 1278-81.
125. Gentile G, Merlo G, Pozzan A, et al. 5-Aryl-4-carboxamide-1,3-oxazoles: Potent and selective GSK-3 inhibitors. Bioorg Med Chem Lett 2012; 22: 1989-94.
126. Saitoh M, Kunitomo J, Kimura E, et al. 2-3-[4-(Alkylsulfinyl) phenyl]-1-benzofuran-5-yl-5-methyl-1,3,4-oxadiazole Derivatives as Novel Inhibitors of Glycogen Synthase Kinase-3β with Good Brain Permeability. J Med Chem 2009; 52: 6270-86.
127. Saitoh M, Kunitomo J, Kimura E, et al. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β. Bioorg Med Chem 2009; 17:2017-29.
128. Bhat R, Xue Y, Berg S, et al. Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor ARA014418. J Biol Chem 2003; 278: 45937-45.
129. Monte FL, Kramer T, Boländer A, et al. Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: An fast and atom efficient access to 1-aryl-3-benzylureas. Bioorg Med Chem Lett 2011; 21: 5610-5.
130. Osolodkin DI, Palyulin VA, Zefirov NS. Structure-based virtual screening of glycogen synthase kinase 3β inhibitors: Analysis of scoring functions applied to large true actives and decoy sets. Chem Biol Drug Des 2011; 78: 378-90.
131. Osolodkin DI. PhD Thesis. Department of Chemistry, Moscow State University. 2011.
132. http://qsar.chem.msu.ru/~dmitry_o/gskdata.html Accessed June 25, 2012.
133. Palyulin VA, Osolodkin DI, Zefirov NS. Virtual screening workflow for glycogen synthase kinase 3β inhibitors: convergence of ligand-based and structure-based approaches. J Cheminf 2011; 3 (Suppl. 1): P17.
134. Karpov PV, Osolodkin DI, Baskin II, Palyulin VA, Zefirov NS. One-class classification as a novel method of ligand-based virtual screening: the case of glycogen synthase kinase 3β inhibitors. Bioorg Med Chem Lett 2011; 21: 6728-31.
135. Cheng YC, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology 1973; 22: 3099-108.
136. Kozikowski AP, Gaisina IN, Petukhov PA, et al. Highly Potent and Specific GSK-3β Inhibitors That Block Tau Phosphorylation and Decrease α-Synuclein Protein Expression in a Cellular Model of Parkinson's Disease. ChemMedChem 2006; 1: 256-66.
137. Ivanova AA, Ivanov AA, Oliferenko AA, Palyulin VA, Zefirov NS. Highly diverse, massive organic data as explored by a composite QSPR strategy: an advanced study of boiling point. SAR QSAR Environ Res 2005; 16: 231-46.
138. Triballeau N, Acher F, Brabet I, Pin JP, Bertrand HO. Virtual Screening Workflow Development Guided by the " Receiver Operating Characteristic" Curve Approach. Application to High-Throughput Docking on Metabotropic Glutamate Receptor Subtype 4. J Med Chem 2005; 48: 2534-47.
139. Truchon JF, Bayly CI. Evaluating Virtual Screening Methods:β Good and Bad Metrics for the "Early Recognition" Problem. J Chem Inf Model 2007; 47: 488-508.
140. Huang N, Shoichet BK, Irwin JJ. Benchmarking Sets for Molecular Docking. J Med Chem 2006; 49: 6789-801.
141. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004; 3: 479-87.
142. Baskin II, Kireeva N, Varnek A. The One-Class Classification Approach to Data Description and to Models Applicability Domain. Mol Inf 2010; 29: 581-7.
143. Karpov PV, Baskin II, Palyulin VA, Zefirov NS. Virtual screening based on one-class classification. Dokl Chem 2011; 437: 107-11.
144. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminf 2011; 3: 33.
145. Briem H, Günther J. Classifying "kinase inhibitor-likeness" by using machine-learning methods. ChemBioChem 2005; 6: 558-66.
146. Witherington J, Bordas V, Haigh D, et al. 5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 2003; 13: 1581-4.
147. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2: 358-64.
148. Martínez A, Castro A, Cardelús I, Llenas J, Palacios J. Arylimino-1,2,4-thiadiazolidinones: A new family of potassium channel openers. Bioorg Med Chem 1997; 5: 1275-83.
149. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: β Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease. J Med Chem 2002; 45: 1292-9.
150. Martinez A, Alonso M, Castro A, et al. SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives:β Exploration of Structural Requirements for Glycogen Synthase Kinase 3 Inhibitors. J Med Chem 2005; 48: 7103-12.
151. Castro A, Encinas A, Gil C, et al. Non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Study of structural requirements for thiadiazolidinone derivatives. Bioorg Med Chem 2008; 16: 495-510.
152. Palomo V, Perez DI, Perez C, et al. 5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. J Med Chem 2012; 55: 1645-61.
153. Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharm Exp Ther 2003; 305: 974-80.
154. Ilouz R, Pietrokovski S, Eisenstein M, Eldar-Finkelman H. New Insights into the Autoinhibition Mechanism of Glycogen Synthase Kinase-3β. J Mol Biol 2008; 383: 999-1007.
155. Eldar-Finkelman H, Licht-Murava A, Pietrokovski S, Eisenstein M. Substrate Competitive GSK-3 Inhibitors strategy and Implications. Biochim Biophys Acta 2010; 1804: 598-603.
156. Licht-Murava A, Plotkin B, Eisenstein M, Eldar-Finkelman H. Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3β and the Refinement of a Competitive Inhibitor. J Mol Biol 2011; 408: 366-78.
157. Rao KV, Donia MS, Peng J, et al. Manzamine B and E and Ircinal A Related Alkaloids from an Indonesian Acanthostrongylophora Sponge and Their Activity against Infectious, Tropical Parasitic, and Alzheimer's Diseases. J Nat Prod 2006; 69: 1034-40.
158. Laport MS, Santos OC, Muricy G. Marine sponges: potential sources of new antimicrobial drugs. Current Pharmaceutical Biotechnology 2009; 10: 86-105.
159. Ibrahim MA, Shilabin AG, Prasanna S, et al. 2-N-Methyl modifications and SAR studies of manzamine A. Bioorg Med Chem 2008; 16: 6702-6.
160. Peng J, Kudrimoti S, Prasanna S, et al. Structure-Activity Relationship and Mechanism of Action Studies of Manzamine Analogues for the Control of Neuroinflammation and Cerebral Infections. J Med Chem 2009; 53: 61-76.
161. El Sayed KA, Khalil AA, Yousaf M, et al. Semisynthetic Studies on the Manzamine Alkaloids. J Nat Prod 2008; 71: 300-8.
162. Shilabin AGG, Kasanah N, Tekwani BL, Hamann MT. Kinetic studies and bioactivity of potential manzamine prodrugs. J Nat Prod 2008; 71:1218-21.
163. Wahba AE, Peng J, Kudrimoti S, Tekwani BL, Hamann MT. Structure-activity relationship studies of manzamine A: Amidation of positions 6 and 8 of the β-carboline moiety. Bioorg Med Chem 2009; 17: 7775-82.
164. Tu LC, Chou CK, Chen CY, Chang YT, Shen YC, Yeh SF. Characterization of the cytotoxic mechanism of Mana-Hox, an analog of manzamine alkaloids. Biochim Biophys Acta 2004; 1672: 148-56.
165. Boursereau Y, Coldham I. Synthesis and biological studies of 1-amino β-carbolines. Bioorg Med Chem Lett 2004; 14: 5841-44.
166. Tu LC, Chen CS, Hsiao IC, et al. The β-Carboline Analog Mana-Hox Causes Mitotic Aberration by Interacting with DNA. Chem Biol 2005; 12: 1317-24.
167. Hsiao CJ, Ho YF, Hsu JTA, et al. Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress. Naunyn-Schmiedeberg's Arch Pharmacol 2008; 378: 599-608.
168. Osolodkin DI, Shulga DA, Palyulin VA, Zefirov NS. Interaction of manzamine A with glycogen synthase kinase 3β: a molecular dynamics study. Russ Chem Bull 2010; 59: 1983-93.
169. Domínguez JMM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem 2012; 287: 893-904.
170. Del Rio A, Sgobba M, Parenti M, et al. A computational workflow for the design of irreversible inhibitors of protein kinases. J Comp-Aided Mol Des 2010; 24: 183-194.
171. Garuti L, Roberti M, Bottegoni G. Irreversible Protein Kinase Inhibitors. Curr Med Chem 2011; 18: 2981-94.
172. Conde S, Pérez DI, Martínez A, Perez C, Moreno FJ. Thienyl and Phenyl α-Halomethyl Ketones:β New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching. J Med Chem 2003; 46: 4631-3.
173. Perez DI, Conde S, Pérez C, et al. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg Med Chem 2009; 17: 6914-25.
174. Perez DI, Palomo V, Pérez C, et al. Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. J Med Chem 2011; 54: 4042-56.
175. Lavogina D, Enkvist E, Uri A. Bisubstrate Inhibitors of Protein Kinases: from Principle to Practical Applications. ChemMedChem 2010; 5: 23-34.